Shopping Cart
- Remove All
Your shopping cart is currently empty
Visugromab (CTL-002) is a monoclonal antibody that targets and neutralises GDF-15. Visugromab exhibits synergistic anticancer activity with the anti-PD1 antibody Nivolumab, making it suitable for PD-1/PD-L1 recurrent/refractory metastatic solid tumours.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $247 | In Stock | |
| 5 mg | $647 | In Stock | |
| 10 mg | $987 | In Stock |
| Description | Visugromab (CTL-002) is a monoclonal antibody that targets and neutralises GDF-15. Visugromab exhibits synergistic anticancer activity with the anti-PD1 antibody Nivolumab, making it suitable for PD-1/PD-L1 recurrent/refractory metastatic solid tumours. |
| In vivo | In preclinical toxicology studies on cynomolgus monkeys, Visugromab (maximum dose of 100 mg/kg, weekly) did not exhibit any signs of toxicity. [2] |
| Synonyms | CTL-002, CTL002 |
| Cas No. | 2556646-63-8 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.